Payment; Reports. All royalty payments due under this Agreement shall be accompanied by a report setting forth, on a country-by-country basis, Net Sales of the Products by Licensee and its Affiliates and Sublicensees in the Licensee Territory in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including, for each country, the number of Products sold, the gross sales and Net Sales of Products, including the deductions from gross sales to arrive at Net Sales, the royalty payable, the exchange rates used, any adjustments to the royalty paid during the Royalty Term pursuant to Section 8.5(c), and whether any Net Sales milestone under Section 8.4 has been achieved. Within ​ following the end of each Calendar Quarter during the Royalty Term and Extended Commercialization Term, Licensee shall provide Ovid with the foregoing report and the payment due for such Calendar Quarter. For clarity, royalty payments during the Extended Commercialization Term shall not be subject to any offsets or reductions whatsoever, including those set forth in Section 8.5(c). Prior to the First Commercial Sale of the Product in the Licensee Territory, the Parties will agree on the form of royalty report. Licensee shall submit a single report for all Net Sales during a Calendar Year, including all of Licensee’s and its Affiliates’ and Sublicensees’ Net Sales, but shall separately identify the Net Sales and other information applicable to each entity.

Payment Reports. Commencing with the Fiscal Quarter during which the First Commercial Sale Date occurs and for each Fiscal Quarter thereafter until the sum of Company’s payments to Bain equal the Product Cap, within ​ after the end of each such Fiscal Quarter, Company shall prepare and deliver a written report to Bain that includes reasonably detailed information regarding total monthly sales calculation of Net Sales including deductions) and all Revenue Share Payments payable to Bain for the applicable Fiscal Quarter (including, any foreign exchange rates employed), which shall be ​ (such written report, a “Payment Report”). For the avoidance of doubt, Company shall provide Bain with a Payment Report pursuant to this [Section 4.1(e)] even if no Revenue Share Payment or Sales Milestone Payment is owed for a given Fiscal Quarter.

Reports; Payment. [[FibroGen:Organization]] will deliver a written report to HFB showing a calculation of the Royalties and whether a Sales Milestone has been achieved, providing Net Sales in sufficient detail to allow HFB to verify Royalties and achievement of Sales Milestones due in a given Calendar Quarter no later than ​ after the end of each Calendar Quarter (each, a “Royalty and Net Sales Report”). All Royalty payments will be payable concurrently with the delivery of the Royalty and Net Sales Report for the applicable Calendar Quarter. All payments under this Agreement will be payable, in full, in U.S. dollars, regardless of the country(ies) in which such sales are made. For purposes of computing the Royalty of any Licensed Product that is sold in a currency other than United States dollars, such currency will be converted into United States dollars at the median of the buying rate and the selling rate of exchange reported by the Wall Street Journal on the last day for the month in which such sales were recorded.

Payment/Reports. All payments under this Section 6.4 shall be due and payable within ​ after ​ during which the corresponding Net Sales or Net Receipts are ​

Reports; Payment. During the Term, Coya shall furnish to ARScience Bio a written report within 45 days after the end of each Calendar Quarter that contains the following information for the applicable Calendar Quarter, on a Product-by-Product basis: # Net Sales (including reasonable detail for deductions from gross sales to Net Sales) in both the local currency in which such amounts are invoiced and Dollars, # the royalties payable under this Article 5 (Payments) specifying in reasonable detail each adjustment, if any, to the royalty rate(s) as provided in Section 5.5 (Royalty Adjustments), and # any Sublicensing Income. Royalties with respect to Net Sales of Products and payments with respect to Sublicensing Income shall be due and payable on the date such report is due.

Payment; Reports. All royalty payments due under this Agreement shall be accompanied by a report setting forth, on a country-by-country basis, Net Sales of the Products by Licensee and its Affiliates and Sublicensees in the Licensee Territory in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including, for each country, the number of Products sold, the gross sales and Net Sales of Products, including the deductions from gross sales to arrive at Net Sales, the royalty payable, the exchange rates used, any adjustments to the royalty paid during the Royalty Term pursuant to Section 8.5(c), and whether any Net Sales milestone under Section 8.4 has been achieved. Within ​ following the end of each Calendar Quarter during the Royalty Term and Extended Commercialization Term, Licensee shall provide Ovid with the foregoing report and the payment due for such Calendar Quarter. For clarity, royalty payments during the Extended Commercialization Term shall not be subject to any offsets or reductions whatsoever, including those set forth in Section 8.5(c). Prior to the First Commercial Sale of the Product in the Licensee Territory, the Parties will agree on the form of royalty report. Licensee shall submit a single report for all Net Sales during a Calendar Year, including all of Licensee’s and its Affiliates’ and Sublicensees’ Net Sales, but shall separately identify the Net Sales and other information applicable to each entity.

Payment/Reports. All payments under this Section II shall be due and payable ​ after the ​ during which the corresponding ​. Together with any such payment, ​ specifying: # ​ during the ​; # ​; and # amounts ​ from ​ to calculate ​.

Payment; Reports. Royalty payments due from Anteris to vTv under [Section 6.6] shall be calculated and reported for each Calendar Quarter during the Royalty Term. Royalty payments due under [Section 6.6] shall be paid within ​ days after the end of each Calendar Quarter and shall be accompanied by a report setting forth the Net Sales of the Licensed Products by Anteris and its Affiliates and Sublicensees in the Territory, the royalties payable, the exchange rates used, and whether any sales milestone under [Section 6.5] has been achieved.

Commencing as of the Effective Date, for so long as any revenue share term remains in effect for the Solution or Enhanced Solution(s), Dario will:

Payment; Reports. Royalty payments due by Lilly to [[Merus:Organization]] under this [Section 8.4] will be calculated and reported for each Calendar Quarter. All Royalty payments due under this [Section 8.4] shall be paid within ​ after the end of each Calendar Quarter and shall be accompanied by a report setting forth Net Sales and Royalties for each Product sold by Lilly and its Affiliates and Sublicensees in the Territory and providing notice of any Commercial Milestone Event that have been achieved in such Calendar Quarter.